Key facts
- · Type: New offering first sale 2026-09-17 · Amount sold: $11.44M · Total offering: $11.94M · SEC filing
- · Type: Amendment first sale 2023-11-21 · Amount sold: $575K · Total offering: $5M · SEC filing
- · Type: New offering first sale 2023-11-21 · Amount sold: $575K · Total offering: $5M · SEC filing
SAN DIEGO, CALIFORNIA
2022
Biotechnology
3
$12.01M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-09-29 | New offering first sale 2026-09-17 | $11.44M | $11.94M | details · SEC filing |
| 2023-12-05 | Amendment first sale 2023-11-21 | $575K | $5M | SEC filing |
| 2023-12-05 | New offering first sale 2023-11-21 | $575K | $5M | SEC filing |
What do you want to do with Vetmab Biosciences, Inc.?
Who to contact
- Denise Bevers — Executive Officer, Director
- Richard Chin — Executive Officer, Director
- Hangjun Zhan — Director
- Neeraj Agrawal — Director
- Chrysa Mineo — Director
- Round: Form D filed 2026-09-29
- Amount sold: $11.44M
- Industry: Biotechnology
- Founded: 2022
- Based: SAN DIEGO, CALIFORNIA
People listed
- Denise Bevers — Executive Officer, Director
- Richard Chin — Executive Officer, Director
- Hangjun Zhan — Director
- Neeraj Agrawal — Director
- Chrysa Mineo — Director
- Filing: Form D filed 2026-09-29
- Amount sold: $11.44M
- Industry group: Biotechnology
- Year formed: 2022
- Based: SAN DIEGO, CALIFORNIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when Vetmab Biosciences, Inc. raises, hires or launches. No email unless you switch it on.
Watch Vetmab Biosciences, Inc. →Want the whole picture on Vetmab Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vetmab Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vetmab Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Vetmab Biosciences, Inc.'s own filings with the SEC. The people those filings name are on the team page.